A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD.
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2014
At a glance
- Drugs AZD 2423 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Biomarker
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 24 Mar 2011 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
- 24 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.